ALLOSTERIS
Live / Allowed — Notice of allowance issued (as of 11 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 10 Dec 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98895371
- Mark type
- Stylized text
- Filed
- 10 Dec 2024
- Published for opposition
- 16 Sept 2025
- Attorney of record
- Clifford D. Hyra
Goods and services
- Class 005 — Pharmaceuticals: (Based on 44(e) Priority Application) Pharmaceutical preparations and substances, namely, pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Pharmaceutical preparations and substances, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; (Based on Intent To Use); Medical preparations and substances, namely, fungal preparations in the nature of fungal medications for medical purposes, probiotic preparations for medical use, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Veterinary preparations in the nature of veterinary pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Biologicals preparations for pharmaceutical, medical and veterinary use, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes, namely, diagnostic preparations for veterinary and medical use, pharmaceutical preparations and biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, autoimmune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Preparations and substances for use in drug discovery, namely, preparations for growing cells or for producing biologicals for medical, pharmaceutical, and veterinary purposes, and reagents and media for medical, pharmaceutical and veterinary diagnostic purposes, namely, media and reagents serving as inoculate, clinical medical reagents, and diagnostic reagents
- Class 042 — Scientific and technological services: Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, autoimmune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical research laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; pharmaceutical drug development services; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research
Owner
Prosecution history
- 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Sept 2025 — PUBLISHED FOR OPPOSITION
- 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Aug 2025 — EXAMINER'S AMENDMENT ENTERED
- 18 Aug 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 18 Aug 2025 — EXAMINERS AMENDMENT E-MAILED
- 18 Aug 2025 — EXAMINERS AMENDMENT -WRITTEN
- 15 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 15 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 03 Jun 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Jun 2025 — NON-FINAL ACTION E-MAILED
- 03 Jun 2025 — NON-FINAL ACTION WRITTEN